Europe’s Innovative Medicines Initiative (IMI) is joining forces with its US counterpart, the Critical Path Institute (C-Path) to further their shared mission of reshaping the drug development process to improve the productivity of pharmaceutical industry R&D.
Both organisations bring together scientists from the industry and academic institutions, with representatives from patient organisations, small companies and regulatory agencies, in precompetitive public-private partnerships.
By combining knowledge and expertise, these partnerships aim to tackle challenges that are too big and complex...
This page requires a Science|Business Network Membership
This page is available to Science|Business Network Members only. If you are already a member then please log in (above).
Note if you are only registered to receive our Bulletin, or have previously purchased an item from our store, this does not give you access to the full benefits of the site. Join Now and plug into the Science|Business Network to get full access to all our news, events and business opportunities.
Science|Business is the first independent media company that brings together researchers, investors and policy makers in the European innovation community. It does so with a top-quality team and unique network of Europe's leading scientific institutions, corporations, policy makers and IP and VC specialists.
Be where innovation begins – become a member. Click here to learn more.